Crossmark

Evidence from a mouse model supports repurposing an anti-asthmatic drug, bambuterol, against Alzheimer’s disease by administration through an intranasal route

Crossref DOI link: https://doi.org/10.1038/s42003-025-07599-7

Published Online: 2025-02-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Groo, Anne-Claire

Curel, Thomas

Malzert-Fréon, Aurélie https://orcid.org/0000-0001-6023-1861
Séguy, Line

Bento, Ophélie https://orcid.org/0000-0002-7857-1642
Corvaisier, Sophie

Culerier, Thomas

Legrand, Romain

Callizot, Noëlle

Henriques, Alexandre

Culley, Georgia

Claeysen, Sylvie https://orcid.org/0000-0002-0576-5518
Rochais, Christophe https://orcid.org/0000-0001-7996-2082
Dallemagne, Patrick https://orcid.org/0000-0002-4845-615X
License Information

Text and Data Mining valid from 2025-02-01

Version of Record valid from 2025-02-01
More Information

Article History

Received: 3 January 2024

Accepted: 23 January 2025

First Online: 1 February 2025

Competing interests

: N Callizot is co-founder of Neuro-Sys, member of the scientific board and consulting for: Alzprotect, Inflectis, Axoltis, Raya Therapeutics, Neuralia. R Legrand, C Rochais and P Dallemagne are co-founders and members of the scientific board of RonomA-Pharma. All other authors declare no competing interests.

Document is current

Any future updates will be listed below